James Black Foundation Limited

Matthew John Tozer

Sarkis Barret Kalindjian

Michael John Pether

Ildiko Maria Buck

Iain Mair McDonald

David John Dunstone

Caroline M Low

Nigel Paul Shankley

Katherine Isobel Steel

Caroline Minli Rachel Low

Jonathan Michael Davies

Elaine Anne Harper

Martin Lyn Hudson

Andrew Smith

Robert Jurgen Van 't Hof

Paul Wright

Rose Mary Sheridan

Andrew Robert Tuffnell

Ian Duncan Linney

Katherine Isobel Mary Steel

Gillian Fairfull Watt

Tracey Cooke

Juha Andrew Clase

Iain Robert Greig

Raymond Fisher

James Black

Robert A Hull

Sonia Patricia Roberts

Michael J Bodkin

Robert Antony David Hull

Jeremy Gilbert Vinter

John David Gaffen

Martin Keith Walker

Elliot James Lilley

David Andrew Sykes

Eric Peter Griffin

Laurence Wright

Katherine Isabel Mary Steel

Compounds of formula (I) and their pharmaceutically acceptable salts are ligands at gastrin and/or cholecystokinin receptors. X and Y are independently &#x2550;N&#x2014;, &#x2014;N(R)&#x2014;(Rbeing selected from H, Me, Et, Pr, Bn, OH and &#x2014;CHCOOR, wherein Rrepresents H, Me, Et, Pr or Bn), &#x2550;CH&#x2014;, &#x2014;O&#x2014; or &#x2014;S&#x2014;; n is from 1 to 4; A is an optionally substituted 5- or 6-membered carbocyclic ring wherein (a) 1 or 2 C atoms may optionally be replaced by N, O and/or S atoms, (b) A is fused with the aromatic group in formula (I) to form a fused bicycle, and (c) the ring containing X and Y is linked to a C atom of A; Ris H or Cto Chydrocarbyl wherein up to three C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; Ris selected from H, Me, Et, Pr and OH, each Rbeing independently selected from H, Me, Et, Pr and OH when n is greater than 1; R(when n is 1) is selected from H, Me, Et and Pr; or (when n is greater than 1) each Ris independently selected from H, Me, Et and Pr, or two Rgroups on neighbouring carbon atoms are linked to form a Cto Ccarbocylic ring, or two Rgroups are absent from neighbouring carbon atoms which are linked by a double bond; or Rand Ron the same carbon atom together represent an &#x2550;O group; Ris Cto Chydrocarbyl wherein up to two C atoms may optionally be replaced by N, O and/or S atoms and up to three H atoms may optionally be replaced by halogen atoms; V is &#x2014;CO&#x2014;NH&#x2014;SO&#x2014;Ph, &#x2014;SO&#x2014;NH&#x2014;CO&#x2014;PH, &#x2014;CHOH, or a group of the formula &#x2014;RU, (wherein U is &#x2014;COOH, tetrazolyl, &#x2014;CONHOH or &#x2014;SOH; and Ris a bond; Cto Chydrocarbylene optionally substituted by hydroxy, amino or acetamido; &#x2014;O&#x2014;(Cto Calkylene)&#x2014;; &#x2014;SONR&#x2014;CHR&#x2014;; &#x2014;CO&#x2014;NR&#x2014;CHR&#x2014;, Rand Rbeing independently selected from H and methyl; or &#x2014;NH&#x2014;(CO)&#x2014;CH, c being 0 or 1); or a pharmaceutically acceptable salt thereof. Compositions comprising a compound a formula (I) are also described

Gastrin and cholecystokinin receptor ligands (III)

Ligands for the gastrin and cholecystokinin (CCK) receptors are provided, together with methods for preparing such ligands, and compounds which are useful intermediates in such methods. Pharmaceutical compositions comprising such ligands, methods for preparing such pharmaceutical compositions, and methods of treatment using these compositions also are provided. The ligands have the formula (I):where n is from 1 to 3;

Gastrin and cholecystokinin receptor ligands(II)

Gastrin and cholecystokinin receptor ligands

1H-4(5)-substituted imidazole derivatives, their preparation and their use as histamine H3 receptor ligands

Histamine H.sub.3 receptor ligands

Sulfonamides and sulfamides as H.sub.3 receptor antagonists

Compounds of formula (Ia), (Ib), or (Ic), wherein A represents a group having two fused rings, or a group of formula (Id), R.sup.1.sub.(m) represents up to 6 substituents, K represents --O--, --S--, --CH.sub.2 --, --N(R.sup.2)-- or --N(COR.sup.2)--, in which R.sup.2 is H or C.sub.1 to C.sub.3 alkyl, W is a carbonyl, sulfonyl or sulfinyl group, provided that at least one of W and X contains carbonyl, Y and Z are as given in the description, and their pharmaceutically acceptable salts are ligands at CCK and/or gastrin receptors. ##STR1##

Gastrin and cck receptor ligands

Gastin and CCK receptor ligands

The compounds of the formula I ##STR1## and their pharmaceutical acceptable salts, which are defined herein, are ligands for cholecystokinin and/or gastrin receptors.

Bicyclo 2,2,2!octane derivatives

Growing community of inventors

London, United Kingdom

Matthew John Tozer